DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga's All-Access. GlucoTrack is a medical technology company ...
Sensors for Medicine and Science (SMSI), which is developing an implantable glucose monitoring sensor, announced this week that it received $54.1 million in fourth round funding. Delphi Ventures led ...
Adults with diabetes using an implantable 1-year continuous glucose monitoring sensor had a mean time in range of about 66% ...
In the rapidly evolving medical technology sector, diabetes management specialist Glucotrack Inc. (NASDAQ: GCTK) aims to disrupt the present care framework for the benefit of patients. Thanks to its ...
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel ...
PARSIPPANY, N.J. & GERMANTOWN, Md.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused ...
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States. “The FDA is committed to advancing novel ...
Glucotrack Inc. (NASDAQ:GCTK) stock traded higher on Wednesday, with a session volume of 15.91 million compared to the average of 81.7K, according to data from Benzinga Pro. The diabetes-focused ...
This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of ...
Paul Goode, President & CEO, GlucoTrack GCTK, was recently a guest on Benzinga's All-Access. GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results